Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733489 | 0.91 | TSPO (0.31) | NR3C1ALDH1A1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL21733646 | 0.89 | HCRTR1 (0.33) | NR3C1ALDH1A1TSPOHCRTR1HCRTR2 | |
| SCHEMBL21733765 | 0.89 | HCRTR1 (0.33) | NR3C1ALDH1A1TSPOHCRTR1HCRTR2 | |
| SCHEMBL21733808 | 0.84 | TSPO (0.35) | NR3C1ALDH1A1TSPOHCRTR1HCRTR2 | |
| SCHEMBL21733848 | 0.83 | CNR1 (0.32) | NR3C1HCRTR1HCRTR2CNR1CNR2 | |
| SCHEMBL21733790 | 0.82 | MEN1 (0.35) | ALDH1A1HCRTR1HCRTR2CNR1CNR2 | |
| SCHEMBL21733814 | 0.80 | ACHE (0.32) | NR3C1TSPOCNR1CNR2PDE10A | |
| SCHEMBL21733854 | 0.79 | NR3C1 (0.37) | NR3C1ALDH1A1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL21733488 | 0.79 | TP53 (0.33) | ALDH1A1TSHRMAPK1SMN1; SMN2TSPO | |
| SCHEMBL21733823 | 0.78 | HCRTR1 (0.32) | HCRTR1HCRTR2CNR1CNR2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112119075-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NR3C1 1398/4885ALDH1A1 3678/4885TSHR 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.